Lantern Pharma Inc. (LTRN): Total Liabilities
$4.50M
As of 2025-12-31
$11.82M
As of 2026-06-30
+17.2%
3-year compound annual growth
+46.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.50M | +2.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $4.38M | +60.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $2.74M | -2.1% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $2.80M | +17.6% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $2.38M | +260.0% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $660.8K | +35.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $489.3K | n/a | 2021-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $4.50M | +2.7% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $5.17M | +241.9% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $702.1K | -2.9% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $5.79M | -30.5% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $4.20M | -52.9% |
| Traws Pharma, Inc. (TRAW) | 2025-12-31 | $11.25M | -80.1% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $361.0K | n/m |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $2.72M | +42.2% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $8.22M | +357.5% |
Compare LTRN, DCOY, MIRA, MTVA side by side · Screen every company in Pharmaceutical Preparations ↗